Immunai, Bristol Myers Squibb sign AI immune-data collaboration
The New York-based AI biotech will use its AMICA-OS platform to analyze clinical immune data for BMS, aiming to inform patient stratification, biomarkers, and trial decisions.
Discuss the story with the TraceFeed community.
No comments yet. Be the first to add a perspective.